Market Overview

Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says

Share:
Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says

Translate Bio Inc (NASDAQ: TBIO) went public by offering 9.35 million shares. The offering was priced at $13 per share on June 28.

The Analyst

With the IPO quiet period expiring, Credit Suisse analyst Yigal Nochomovitz initiated coverage of shares with a Buy rating and a $20 price target.

The Thesis

mRNA replacement therapy, which Translate Bio uses to treat diseases caused by protein defects or deficiencies, is transient or biodegradable and carries a lower risk of off-target effects relative to gene therapy, analyst Nochomovitz said in a Monday morning note.

The analyst noted the company's lead clinical candidate MRT5005 is in Phase 1/2 study for cystic fibrosis. MRT5005 is designed to be used in all cystic fibrosis points, regardless of CFTR mutation, the analyst added.

MRT5005 was found to induce robust CFTR protein expression in pre-clinical studies, Nochomovitz said. The candidate addresses a key investor concern due to its ability to successfully diffuse across the human CF mucus layer.

Price Action

Since listing with a loss of 11.4 percent on its debut, Translate Bio shares have gained about 38.4 percent.

Related Link:

Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

Latest Ratings for TBIO

DateFirmActionFromTo
Jul 2019Initiates Coverage OnBuy
Jun 2019Initiates Coverage OnBuy
Dec 2018Initiates Coverage OnBuy

View More Analyst Ratings for TBIO
View the Latest Analyst Ratings

Posted-In: Citigroup Yigal NochomovitzAnalyst Color Initiation Analyst Ratings Best of Benzinga

 

Related Articles (TBIO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
RNRJP MorganAssumes173.0
CARBNorthlandDowngrades23.0
GLIBACitiUpgrades80.0
PBHTD SecuritiesMaintains100.0
BEP.PR.ETD SecuritiesDowngrades45.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Bank Of America Appreciates Caesars Entertainment's 'Dramatically Restructured' Balance Sheet

Alphabet Q2 Earnings Preview